Efficacy of Lebrikizumab in Patients with Atopic Dermatitis and Atopic Comorbidities: Pooled Results from 2 Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)

Sebastian Volc, Ellen R. Sher,Mark Boguniewicz, Alexandra K. Golant,Marjolein S. de Bruin-Weller,Jose-Manuel Carrascosa,Jinglin Zhong,Zach Dawson,Amber Reck Atwater,Kimberly Siu,Jacob P. Thyssen

Journal of Allergy and Clinical Immunology（2023）

引用 0|浏览5

暂无评分

摘要

Atopic comorbidities are common in patients with atopic dermatitis (AD). We evaluated lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, in patients with AD with and without atopic comorbidities in 2 Phase 3, randomized, double-blind trials (ADvocate1 [NCT04146363] and ADvocate2 [NCT04178967]).

查看译文

关键词

atopic dermatitis,lebrikizumab,atopic comorbidities,monotherapy,double-blind,placebo-controlled

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要